Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging melanoma vaccines.

Jean-Claude Bystryn1, Jennifer L Rudolph

  • 1New York University School of Medicine, The Ronald O. Perelman Department of Dermatology, NYU Cancer Institute, New York, NY, USA. bystryn@nyu.edu

Expert Opinion on Emerging Drugs
|June 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rit GTPase regulates a p38 MAPK-dependent neuronal survival pathway.

Neuroscience letters·2012
Same author

Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.

Journal of the American Academy of Dermatology·2011
Same author

Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.

Autoimmunity·2011
Same author

An evolutionarily conserved Rit GTPase-p38 MAPK signaling pathway mediates oxidative stress resistance.

Molecular biology of the cell·2011
Same author

Serum levels of inhibitors of apoptotic proteins (IAPs) change with IVIg therapy in pemphigus.

The Journal of investigative dermatology·2011
Same author

Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies.

Journal of the American Academy of Dermatology·2010
Same journal

σ<sub>1</sub> receptor agonists: the new trend or an emerging therapeutic option?

Expert opinion on emerging drugs·2026
Same journal

Obefazimod (ABX464) for moderate-to-severe Crohn's disease: clinical development of a novel oral therapeutic approach.

Expert opinion on emerging drugs·2026
Same journal

Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease.

Expert opinion on emerging drugs·2026
Same journal

Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond.

Expert opinion on emerging drugs·2026
Same journal

Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies.

Expert opinion on emerging drugs·2026
Same journal

Acute management of adult MOG antibody-associated disease: therapeutic choices and clinical outcomes.

Expert opinion on emerging drugs·2026
See all related articles

Advanced melanoma lacks effective treatments. Polyvalent melanoma vaccines, containing multiple antigens, show promise in clinical trials by delaying tumor progression and stimulating immune responses.

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Melanoma that has metastasized lacks effective treatments.
  • Interferon-alpha2b (IFN-alpha2b) is the only FDA-approved therapy for advanced melanoma.
  • Current melanoma vaccines aim to stimulate the immune system against tumor cells.

Purpose of the Study:

  • To evaluate the clinical effectiveness of polyvalent melanoma vaccines.
  • To explore strategies for improving melanoma vaccine efficacy.
  • To identify key challenges in developing advanced melanoma treatments.

Main Methods:

  • Review of two randomized trials of polyvalent melanoma vaccines (NeoVac and Melacine).
  • Analysis of vaccine-induced immune responses and tumor progression.

Related Experiment Videos

  • Consideration of human leukocyte antigen (HLA) phenotypes in treatment response.

    • Main Results:

    • Both reviewed vaccines demonstrated a delay in tumor progression in treated patients.
    • Melacine's efficacy was linked to specific human leukocyte antigen (HLA) phenotypes.
    • Ongoing Phase III trials are investigating other melanoma vaccines.

    Conclusions:

    • Polyvalent melanoma vaccines represent a promising therapeutic strategy for advanced melanoma.
    • Further research is needed to optimize vaccine antigen selection and adjuvant development.
    • Enhancing immune response magnitude and frequency is crucial for clinical benefit.